scispace - formally typeset
Search or ask a question
Author

Siqi Wang

Bio: Siqi Wang is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 3, co-authored 7 publications receiving 35 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: In this article, the use of nanotechnology for the imaging of predictive biomarkers and the combination with other therapeutic modalities presents a number of advantages for the immunotherapy of breast cancer patients.
Abstract: Immunotherapy is a major emerging treatment for breast cancer (BC). However, not all breast cancer patients derive benefit from immunotherapy. Predictive biomarkers of immunotherapy, such as tumor mutation burden and tumor-infiltrating lymphocytes, are promising to stratify the patients with BC and optimize the therapeutic effect. Various targets of the immune response pathway have also been explored to expand the modalities of immunotherapy. The use of nanotechnology for the imaging of predictive biomarkers and the combination with other therapeutic modalities presents a number of advantages for the immunotherapy of BC. In this review, we summary the emerging therapeutic modalities of immunotherapy, present prominent examples of immunotherapy in BC, and discuss the future opportunity of nanotechnology in the immunotherapy of BC.

22 citations

Journal ArticleDOI
Yanni Jiang1, Jianjuan Lou1, Siqi Wang1, Yi Zhao1, Cong Wang1, Dehang Wang1 
13 Jun 2014-PLOS ONE
TL;DR: Dynamic contrast-enhanced MR imaging of breast is able to be applied to predict the risk of malignance before follow-up for BI-RADS 3 microcalcifications and biopsy for BI -RADS 4 micro Calcifications.
Abstract: Objective The purpose of study was to prospectively evaluate the diagnostic performance of dynamic contrast-enhanced MR imaging in the differentiation of malignant lesions from benign ones in patients with BI-RADS 3–4 microcalcifications detected by mammography. Materials and Methods 93 women with 100 microcalcifications had undergone breast MRI from June 2010 to July 2013. Subsequently, 91 received open biopsy and 2 received stereotactic vacuum-assisted biopsy. All results were compared with histological findings. The PPV, NPV and area under curve (AUC) of the mammography and breast MRI were calculated. Results There were 31 (31.0%) BI-RADS 3 microcalcifications and 69 (69.0%) BI-RADS 4. The PPV and NPV of mammography is 65.2% (45/69) and 90.3% (28/31). The PPV and NPV of breast MRI was 90.2% (46/51) and 95.9% (47/49). Among 31 BI-RADS 3 microcalcifications, the PPV and NPV of breast MRI was 100% (3/3) and 100% (28/28). Among 69 BI-RADS 4 microcalcifications, the PPV and NPV of breast MRI was 89.6% (43/48) and 90.5% (19/21). The AUC of mammography and breast MRI assessment were 0.738 (95% CI, 0.639–0.837) and 0.931 (95% CI, 0.874–0.988) (p<0.05). Conclusion Dynamic contrast-enhanced MR imaging of breast is able to be applied to predict the risk of malignance before follow-up for BI-RADS 3 microcalcifications and biopsy for BI-RADS 4 microcalcifications.

18 citations

Journal ArticleDOI
TL;DR: SIslope and ADC10 are significant predictors for breast malignancy and the combination of DCE-MRI and DWI improves differentiating performance.

15 citations

Journal ArticleDOI
TL;DR: In this article, the expression status and prognostic value of monocarboxylate transporter 4 (MCT4) in breast cancer was investigated through large-scale transcriptome data.
Abstract: Lactate blunts the anticancer immune response in breast cancer (BC). However, little is known about the exact effect of lactate transporters such as monocarboxylate transporter 4 (MCT4) on immunotherapy. In this study, we investigated the expression status and prognostic value of MCT4 in BC through large-scale transcriptome data. Our results showed that MCT4 was overexpressed in BC, particularly in the basal-like molecular subtype. Overexpression of MCT4 was significantly correlated with high BC lesion grade and poor prognosis. Enrichment analysis indicated that the MCT4-related genes were involved in immune- and metabolism-related bioprocesses, such as myeloid leukocyte activation, the adaptive immune system, and catabolic process. We also found that the expression of MCT4 in BC lesions was associated with immune cell infiltration and glycolytic rate-limiting enzymes like pyruvate kinase M2 (PKM2) and hexokinases-3 (HK3). Our observations indicate that MCT4 may play a pivotal role in the maintenance of the tumor immune microenvironment (TIME) through metabolic reprogramming. The enzymes of the glycolysis pathway (MCT4, PKM2, and HK3) may thus serve as new targets to modulate the TIME and enhance immunotherapy efficiency.[Figure: see text].

13 citations

Journal ArticleDOI
TL;DR: Circumscribed margin and rim enhancement on s-MRI and ADC90 are three important elements in detecting TNBC, while ADC histogram analysis can provide additional value in this detection.
Abstract: Background Triple-negative breast cancers generally occur in young women with remarkable potential to be aggressive. It will be of great help to detect this subtype of tumor early. To retrospectively evaluate the performance of histogram analysis of apparent diffusion coefficient (ADC) maps in distinguishing triple-negative breast cancer (TNBC) from other subtypes of breast cancer (non-TNBC), when combined with magnetic resonance imaging (MRI) features. Materials and methods From February 2014 to December 2018, 192 patients were included in this study taking preoperative standard MRI (s-MRI) and DWI. Seventy-six of them were pathologically confirmed with TNBC and rest 116 with other subtypes. First, their clinical-pathological features and morphological characteristics on MRI were assessed, including tumor size, foci quantity, tumor shape, margin, internal enhancement, and time-signal intensity curve types, in addition to the signal intensity on T2-weighted images. Second, whole-lesion apparent diffusion coefficient (ADC) histogram analysis was executed. Finally, both univariate and multivariate regression analyses were applied to identify the most useful variables in separating TNBCs from non-TNBCs, and then their effects were evaluated following receiver operating characteristic curve analysis. Result Multivariate regression analysis indicated that circumscribed margin, rim enhancement, and ADC90 were important predictors for TNBC. Increased area under curve (AUC) and improved specificity can be obtained when combined s-MRI and DWI (circumscribed margin+rim enhancement+ADC90>1.47×10-3 mm2/s) is taken as the criterion, other than s-MRI (circumscribed margin+rim enhancement) alone (s-MRI+DWI vs s-MRI; AUC, 0.833 vs 0.797; specificity, 98.3% vs 89.7%; sensitivity, 68.4% vs 69.7%). Conclusion Circumscribed margin and rim enhancement on s-MRI and ADC90 are three important elements in detecting TNBC, while ADC histogram analysis can provide additional value in this detection.

10 citations


Cited by
More filters
Journal ArticleDOI
02 Aug 2016-PLOS ONE
TL;DR: In this paper, the authors performed a systematic review and meta-analysis of peer-reviewed studies in PubMed from 1/01/1986 until 06/15/2015, evaluating the performance of MRI for diagnosis of breast cancer in non-calcified equivocal breast findings.
Abstract: Objectives To evaluate the performance of MRI for diagnosis of breast cancer in non-calcified equivocal breast findings. Materials and Methods We performed a systematic review and meta-analysis of peer-reviewed studies in PubMed from 01/01/1986 until 06/15/2015. Eligible were studies applying dynamic contrast-enhanced breast MRI as an adjunct to conventional imaging (mammography, ultrasound) to clarify equivocal findings without microcalcifications. Reference standard for MRI findings had to be established by histopathological sampling or imaging follow-up of at least 12 months. Number of true or false positives and negatives and other characteristics were extracted, and possible bias was determined using the QUADAS-2 applet. Statistical analyses included data pooling and heterogeneity testing. Results Fourteen out of 514 studies comprising 2,316 lesions met our inclusion criteria. Pooled diagnostic parameters were: sensitivity (99%, 95%-CI: 93–100%), specificity (89%, 95%-CI: 85–92%), PPV (56%, 95%-CI: 42–70%) and NPV (100%, 95%-CI: 99–100%). These estimates displayed significant heterogeneity (P<0.001). Conclusions Breast MRI demonstrates an excellent diagnostic performance in case of non-calcified equivocal breast findings detected in conventional imaging. However, considering the substantial heterogeneity with regard to prevalence of malignancy, problem solving criteria need to be better defined.

104 citations

Journal ArticleDOI
TL;DR: Breast MR imaging is not recommended for diagnosis of malignancy in BI-RADS 3 and 5 mammographic microcalcifications, but can be considered for BI- RADS 4 mammographicmicrocalcification.
Abstract: The results of this meta-analysis support the application of MR imaging for the diagnosis of malignancy in mammographic microcalcifications classified as Breast Imaging Reporting and Data System 4 if patients are preselected correctly and if the presence of enhancement is the sole diagnostic criterion

103 citations

Journal ArticleDOI
TL;DR: An ADC threshold of 1.00 × 10− 3 mm2/s can be recommended for distinguishing breast cancers from benign lesions, independent on Tesla strength, choice of b values, and measure methods.
Abstract: The purpose of the present meta-analysis was to provide evident data about use of Apparent Diffusion Coefficient (ADC) values for distinguishing malignant and benign breast lesions. MEDLINE library and SCOPUS database were screened for associations between ADC and malignancy/benignancy of breast lesions up to December 2018. Overall, 123 items were identified. The following data were extracted from the literature: authors, year of publication, study design, number of patients/lesions, lesion type, mean value and standard deviation of ADC, measure method, b values, and Tesla strength. The methodological quality of the 123 studies was checked according to the QUADAS-2 instrument. The meta-analysis was undertaken by using RevMan 5.3 software. DerSimonian and Laird random-effects models with inverse-variance weights were used without any further correction to account for the heterogeneity between the studies. Mean ADC values including 95% confidence intervals were calculated separately for benign and malign lesions. The acquired 123 studies comprised 13,847 breast lesions. Malignant lesions were diagnosed in 10,622 cases (76.7%) and benign lesions in 3225 cases (23.3%). The mean ADC value of the malignant lesions was 1.03 × 10− 3 mm2/s and the mean value of the benign lesions was 1.5 × 10− 3 mm2/s. The calculated ADC values of benign lesions were over the value of 1.00 × 10− 3 mm2/s. This result was independent on Tesla strength, choice of b values, and measure methods (whole lesion measure vs estimation of ADC in a single area). An ADC threshold of 1.00 × 10− 3 mm2/s can be recommended for distinguishing breast cancers from benign lesions.

53 citations

Journal ArticleDOI
TL;DR: Novel targeted breast cancer treatments are summarized and the possible implications of combination therapy are explored, including immunotherapy and targeted therapy against critical checkpoints and/or pathways in cell growth.
Abstract: In the United States, breast cancer is among the most frequently diagnosed cancers in women. Breast cancer is classified into four major subtypes: human epidermal growth factor receptor 2 (HER2), Luminal-A, Luminal-B, and Basal-like or triple-negative, based on histopathological criteria including the expression of hormone receptors (estrogen receptor and/or progesterone receptor) and/or HER2. Primary breast cancer treatments can include surgery, radiation therapy, systemic chemotherapy, endocrine therapy, and/or targeted therapy. Endocrine therapy has been shown to be effective in hormone receptor-positive breast cancers and is a common choice for adjuvant therapy. However, due to the aggressive nature of triple-negative breast cancer, targeted therapy is becoming a noteworthy area of research in the search for non-endocrine-targets in breast cancer. In addition to HER2-targeted therapy, other emerging therapies include immunotherapy and targeted therapy against critical checkpoints and/or pathways in cell growth. This review summarizes novel targeted breast cancer treatments and explores the possible implications of combination therapy.

29 citations